Viveve Medical, Inc. (NASDAQ: VIVE) today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Viveve Medical (VIVE) Prices 13.33M Share Common Offering at$1.50/ShDecember 7, 2018 5:45 AM Viveve Medical (VIVE) Announces Proposed Common Share OfferingDecember 6, 2018 4:03 PM Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility StudyDecember 6, 2018 4:03 PM